以Bevacizumab治療子宮內膜癌的檢視

The Role of Bevacizumab in Endometrial Cancer

子宮內膜癌的發生率和死亡率均有增加的趨勢，晚期及復發性子宮內膜癌患者必定跟著增加，治療此類病患成為重要的課題。根據統計顯示，手術外加採骨盆腔放射線治療可減少局部病灶的復發，加用化學治療則可降低遠端轉移。另外，在子宮內膜癌的腫瘤細胞內，血管內皮層生長因子和微血管密度增加越多，則預後越差。Bevacizumab（Avastin癌思停）乃一種抗血管生長因子藥物，被證實能抑制子宮內膜癌細胞的生長，可單獨或合併化學藥物、放射線來治療子宮內膜癌。但需更多的研究，才知理想的劑量和使用時間的長短。

Death rates for endometrial cancer have increased rapidly. Therefore, it is essential to develop effective new methods for the treatment of patients with advanced or recurrent endometrial cancer. Prior studies have indicated that pelvic radiation therapy may decrease the risk of local recurrence, while chemotherapy may reduce the risk of distant metastasis. Increased levels of vascular endothelial growth factor and microvessel density are associated with poor outcome of patients with endometrial cancer. Evidence showed that the addition of bevacizumab, an antiangiogenic agent, may further reduce the risk of local and metastatic lesions. Future regimen will be needed to increase response rates and decrease toxicity.